On May 3, Axinn partner Chad Landmon spoke at the Food and Drug Law Institute's Annual Conference in Washington, DC. The conference provided a forum to discuss the most current advances and forthcoming topics of interest in FDA law. Chad's presentation specifically focused on developments regarding biosimilars.